Fampridine-SR

PreclinicalSmall molecule

AAcorda Therapeutics

Fampridine-SR is one of 53 small molecule programs targeting Cognitive impairment. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

Competition

Competitive Landscape

72 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Exelon

Novartis

Approved

5 2

Ritalin

Novartis

Approved

3 3

Cymbalta

Jazz Pharmaceuticals

Approved

1 4

Aldactone

Pfizer

Approved

1 5

Brintellix

Marinol

Intropin

Glucophage

3 9

Lithobid

SSolvay Pharmaceuticals

Approved

2 10

Coumadin

AAbbott

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Sclerosis7 trials

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

Completed·AAcorda Therapeutics·Phase 3·NCT00483652·240 enrolled

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

Completed·AAcorda Therapeutics·Phase 3·NCT00654927·177 enrolled

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

Completed·AAcorda Therapeutics·Phase 2·NCT00053417·206 enrolled

Show 4 more trials

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

Completed·AAcorda Therapeutics·Phase 3·NCT00648908·269 enrolled

Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?

Completed·LLondon Health Sciences Centre·Phase 2/3·NCT01667497·60 enrolled

Study of Oral Fampridine-SR in Multiple Sclerosis

Completed·AAcorda Therapeutics·Phase 3·NCT00127530·300 enrolled

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

Completed·AAcorda Therapeutics·Phase 3·NCT00649792·214 enrolled

Memory3 trials

Influence of Fampridine on Working Memory in Healthy Subjects

Withdrawn·PProf. Dominique de Quervain, MD·Phase 2·NCT04516603

Influence of Fampridine on Working Memory in Healthy Young Subjects

Completed·PProf. Dominique de Quervain, MD·Phase 2·NCT04652557·44 enrolled

Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression

Recruiting·UUniversity of Basel·Phase 2·NCT06751784·38 enrolled

Spinal Cord Injury2 trials

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

Completed·AAcorda Therapeutics·Phase 3·NCT00041717·213 enrolled

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

Completed·AAcorda Therapeutics·Phase 3·NCT01683838·204 enrolled

Cognitive impairment1 trial

Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive Impairment

Terminated·PProf. Dominique de Quervain, MD·N/A·NCT05274477·8 enrolled

Outcome1 trial

FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra

Completed·UUniversity of Southern Denmark·Phase 4·NCT01656148·108 enrolled

1 more indication

Optic Neuritis1 trial

Fampridine-SR and Optic Neuritis Recovery

Unknown status·CCourtney Casserly·Phase 1·NCT04148781·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Fampridine-SR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fampridine-SR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fampridine-SR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Acorda Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAcorda Therapeutics

Fampridine-SR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Sclerosis7 trials

Memory3 trials

Spinal Cord Injury2 trials

Cognitive impairment1 trial

Outcome1 trial

Optic Neuritis1 trial

References

Drug Info

Quick Facts

Related News